Literature DB >> 18507020

Down-regulation of CD28, TCR-zeta (zeta) and up-regulation of FAS in peripheral cytotoxic T-cells of primary breast cancer patients.

I V Gruber1, S El Yousfi, S Dürr-Störzer, D Wallwiener, E F Solomayer, T Fehm.   

Abstract

BACKGROUND: Several studies have supported the hypothesis that the concept of immuno-surveillance would not be effective in cancer patients. One reason for suppression of antitumor immunity may be attributed to immune impairment of T-lymphocytes, which extends beyond the tumor-microenvironment and might effect the peripheral blood. Therefore the aim of this study was to investigate the expression of immunoregulatory antigens in peripheral blood lymphocytes of primary breast cancer patients in comparison with healthy donors.
MATERIALS AND METHODS: The peripheral blood immune status of 61 patients with primary breast cancer was analysed by FACS-analysis. The different lymphocytic subpopulations were identified by intracellular/extracellular monoclonal antibodies in three-color flow cytometry. The distribution was compared to age-matched healthy female donors (n = 29).
RESULTS: The expression of TCR zeta-chain, an important signal complex for T-cell activation and functional integrity of specific immune response, was significantly reduced in the cytotoxic specific T-cell population. Cytotoxic T-cells (CD3+/CD8+) also showed a down-regulation of CD28, the important ligand to the co-stimulatory molecule CD80 (B7.1) on antigen-presenting cells. Moreover, breast cancer patients had significantly more CD95 (FAS) expressing cytotoxic T-cells than their healthy counterparts (p < 0.05).
CONCLUSION: The significant up-regulation of CD95 and down-regulation of TCR zeta and CD28 in peripheral cytotoxic T-cells of breast cancer patients leads to the hypothesis of systemic immunosuppression, which could open the door for tumor cell dissemination via the blood stream and which is the subject of ongoing studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18507020

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  23 in total

1.  Role of CD8 T Cell Replicative Senescence in Human Aging and in HIV-mediated Immunosenescence.

Authors:  Jeffrey N Dock; Rita B Effros
Journal:  Aging Dis       Date:  2011-10       Impact factor: 6.745

2.  The novel immunotherapeutic molecule T11TS modulates glioma-induced changes of key components of the immunological synapse in favor of T cell activation and glioma abrogation.

Authors:  Suhnrita Chaudhuri; Manoj Kumar Singh; Debanjan Bhattacharya; Sagar Acharya; Sirshendu Chatterjee; Pankaj Kumar; Pushpak Bhattacharjee; Anjan Kumar Basu; Gaurisankar Sa; Tanya Das; Tushar Kanti Ghosh; Swapna Chaudhuri
Journal:  J Neurooncol       Date:  2014-07-16       Impact factor: 4.130

3.  CD28neg. T lymphocytes of a melanoma patient harbor tumor immunity and a high frequency of germline-encoded and public TCRs.

Authors:  Hisayoshi Hashimoto; Marco Sterk; Karin Schilbach
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

Review 4.  Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape.

Authors:  Malte Mohme; Sabine Riethdorf; Klaus Pantel
Journal:  Nat Rev Clin Oncol       Date:  2016-09-20       Impact factor: 66.675

5.  Intravenous ascorbic acid to prevent and treat cancer-associated sepsis?

Authors:  Thomas E Ichim; Boris Minev; Todd Braciak; Brandon Luna; Ron Hunninghake; Nina A Mikirova; James A Jackson; Michael J Gonzalez; Jorge R Miranda-Massari; Doru T Alexandrescu; Constantin A Dasanu; Vladimir Bogin; Janis Ancans; R Brian Stevens; Boris Markosian; James Koropatnick; Chien-Shing Chen; Neil H Riordan
Journal:  J Transl Med       Date:  2011-03-04       Impact factor: 5.531

Review 6.  Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade.

Authors:  Leisha A Emens
Journal:  Expert Rev Anticancer Ther       Date:  2012-12       Impact factor: 4.512

Review 7.  T cell replicative senescence in human aging.

Authors:  Jennifer P Chou; Rita B Effros
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 8.  Aging, nutrient signaling, hematopoietic senescence, and cancer.

Authors:  Priya Balasubramanian; Valter D Longo
Journal:  Crit Rev Oncog       Date:  2013

9.  GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells.

Authors:  Johanna K Morales; Maciej Kmieciak; Keith L Knutson; Harry D Bear; Masoud H Manjili
Journal:  Breast Cancer Res Treat       Date:  2009-11-08       Impact factor: 4.872

Review 10.  Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment.

Authors:  Yangjing Zhao; Qixiang Shao; Guangyong Peng
Journal:  Cell Mol Immunol       Date:  2019-12-18       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.